NCI Discovers Gene Variations From Existing Databases

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

BETHESDA, Md-Using new computer software to “mine” existing databases, National Cancer Institute (NCI) scientists have discovered 10,435 possible new variations in human genes. The so-called single nucleotide polymorphisms, or SNPs, must still be validated, but NCI said each of the variations met statistical confidence levels of 0.99%.

BETHESDA, Md—Using new computer software to “mine” existing databases, National Cancer Institute (NCI) scientists have discovered 10,435 possible new variations in human genes. The so-called single nucleotide polymorphisms, or SNPs, must still be validated, but NCI said each of the variations met statistical confidence levels of 0.99%.

SNPs are considered likely influences on how fast a cancer grows and how well it responds to treatment. However, finding and understanding the variations has posed a considerable technical challenge, one eased somewhat by the special software used by the NCI scientists, noted team leader Kenneth Buetow, PhD.

Information on the new SNPs is available free to researchers on the NCI’s Cancer Genome Anatomy Project website (http://lpg.nci.nih.gov).

Recent Videos
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
A panel of 5 experts on multiple myeloma